Weaver Capital Management LLC Grows Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Weaver Capital Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 16.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,741 shares of the company’s stock after acquiring an additional 248 shares during the quarter. Weaver Capital Management LLC’s holdings in Zoetis were worth $302,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ZTS. Focus Financial Network Inc. ADV purchased a new position in Zoetis in the 4th quarter worth approximately $2,159,000. Price T Rowe Associates Inc. MD lifted its position in shares of Zoetis by 31.0% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares in the last quarter. Axiom Investors LLC DE boosted its stake in Zoetis by 36.3% during the fourth quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock valued at $117,331,000 after buying an additional 158,459 shares during the last quarter. Global Assets Advisory LLC bought a new position in shares of Zoetis during the 1st quarter valued at approximately $8,831,000. Finally, Cary Street Partners Investment Advisory LLC grew its holdings in shares of Zoetis by 3.3% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 96,810 shares of the company’s stock valued at $19,107,000 after purchasing an additional 3,075 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Zoetis stock opened at $187.33 on Thursday. The company has a 50 day moving average price of $180.70 and a 200-day moving average price of $174.48. The company has a market capitalization of $85.48 billion, a PE ratio of 36.09, a P/E/G ratio of 2.81 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same quarter in the prior year, the company earned $1.41 EPS. The business’s revenue was up 8.3% compared to the same quarter last year. As a group, equities analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on ZTS. HSBC lowered their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus restated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a report on Tuesday, August 27th. Finally, BTIG Research increased their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and a consensus target price of $217.11.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.